Dapagliflozin shows efficacy as add-on to sitagliptin

11/14/2013 | Medscape (free registration)

Type 2 diabetes patients who used dapagliflozin as an add-on to sitagliptin treatment attained a 24.9% increase in beta-cell function from baseline, compared with a 5.2% increase in the placebo group, according to a study in Diabetes Care. Researchers also found more patients in the dapagliflozin arm had A1C levels below 7.0% than those who took a placebo. However, dapagliflozin was tied to higher genital infection rates in patients, researchers added.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD